Additionally, it was covered by insurance in Japan in May 2024, and the detection of PIK3CA, AKT1, and PTEN alterations by FoundationOne CDx is a companion diagnosis for the use of capivasertib in HR-positive HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations. This evidence concerns the gene ERBB2 and breast cancer.